BLFS vs. SLNO, INMD, ZYXI, EDAP, AXGN, OM, CNMD, LIVN, ITGR, and INVA
Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Soleno Therapeutics (SLNO), InMode (INMD), Zynex (ZYXI), Edap Tms (EDAP), AxoGen (AXGN), Outset Medical (OM), CONMED (CNMD), LivaNova (LIVN), Integer (ITGR), and Innoviva (INVA). These companies are all part of the "medical" sector.
Soleno Therapeutics (NASDAQ:SLNO) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.
97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are held by institutional investors. 12.3% of Soleno Therapeutics shares are held by insiders. Comparatively, 2.7% of BioLife Solutions shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Soleno Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500.
Soleno Therapeutics has higher earnings, but lower revenue than BioLife Solutions. Soleno Therapeutics is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.
BioLife Solutions received 1 more outperform votes than Soleno Therapeutics when rated by MarketBeat users. However, 71.43% of users gave Soleno Therapeutics an outperform vote while only 66.74% of users gave BioLife Solutions an outperform vote.
Soleno Therapeutics currently has a consensus price target of $60.33, suggesting a potential upside of 28.62%. BioLife Solutions has a consensus price target of $23.67, suggesting a potential upside of 8.46%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe Soleno Therapeutics is more favorable than BioLife Solutions.
Soleno Therapeutics has a net margin of 0.00% compared to Soleno Therapeutics' net margin of -45.84%. Soleno Therapeutics' return on equity of -12.89% beat BioLife Solutions' return on equity.
In the previous week, BioLife Solutions had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 7 mentions for BioLife Solutions and 5 mentions for Soleno Therapeutics. Soleno Therapeutics' average media sentiment score of 1.03 beat BioLife Solutions' score of 0.10 indicating that BioLife Solutions is being referred to more favorably in the news media.
Summary
Soleno Therapeutics and BioLife Solutions tied by winning 9 of the 18 factors compared between the two stocks.
Get BioLife Solutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLFS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLife Solutions Competitors List
Related Companies and Tools
